IFRX vs. ASMB, ELYM, MNOV, KZR, EYEN, CNTB, EGRX, KRON, TPST, and DERM
Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Assembly Biosciences (ASMB), Eliem Therapeutics (ELYM), MediciNova (MNOV), Kezar Life Sciences (KZR), Eyenovia (EYEN), Connect Biopharma (CNTB), Eagle Pharmaceuticals (EGRX), Kronos Bio (KRON), Tempest Therapeutics (TPST), and Journey Medical (DERM). These companies are all part of the "pharmaceutical preparations" industry.
Assembly Biosciences (NASDAQ:ASMB) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Assembly Biosciences received 10 more outperform votes than InflaRx when rated by MarketBeat users. However, 63.99% of users gave InflaRx an outperform vote while only 59.65% of users gave Assembly Biosciences an outperform vote.
19.9% of Assembly Biosciences shares are held by institutional investors. Comparatively, 48.2% of InflaRx shares are held by institutional investors. 4.1% of Assembly Biosciences shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Assembly Biosciences presently has a consensus price target of $18.00, suggesting a potential upside of 52.54%. InflaRx has a consensus price target of $11.67, suggesting a potential upside of 677.78%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than Assembly Biosciences.
Assembly Biosciences' return on equity of -33.62% beat InflaRx's return on equity.
InflaRx has lower revenue, but higher earnings than Assembly Biosciences. InflaRx is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Assembly Biosciences has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
In the previous week, Assembly Biosciences had 29 more articles in the media than InflaRx. MarketBeat recorded 31 mentions for Assembly Biosciences and 2 mentions for InflaRx. Assembly Biosciences' average media sentiment score of 1.44 beat InflaRx's score of 0.02 indicating that InflaRx is being referred to more favorably in the news media.
Summary
InflaRx beats Assembly Biosciences on 13 of the 17 factors compared between the two stocks.
Get InflaRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools